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To the Editor: Valvular aortic stenosis (AS) leads to several path-
ophysiological changes. These result in cardiac dysfunction, with
attendant symptoms and, if not managed appropriately, poor
clinical outcomes. Impairment of coronary ﬂow dynamics, as
measured by coronary ﬂow reserve (CFR), has been identiﬁed as
a likely major contributor toward the adverse outcomes that occur
in patients with severe AS (1,2). We therefore sought to assess the
effect of transcatheter aortic valve implantation (TAVI) on coro-
nary ﬂow dynamics as assessed by invasive CFR measurement in
patients undergoing TAVI for severe AS.
The study design consisted of enrollment of consecutive patients
undergoing transfemoral TAVI for severe AS at University Hos-
pital, London Health Sciences Centre, London, Ontario, Canada.
Inclusion criteria included documented symptomatic severe AS
(aortic valve mean gradient on transthoracic echocardiography
of >40 mm Hg, peak aortic valve velocity of >4 m/s, and aortic
valve area of <1.0 cm2), high risk to undergo conventional aortic
valve replacement, and planned for transfemoral TAVI procedure
in a hybrid operating room equipped with angiographic equipment.
Patients undergoing TAVI via the transaortic or transapical
approach were excluded. The study protocol was reviewed and
approved by the ethics board of the University of Western Ontario,
and patients gave written informed consent.
CFR was assessed at the time of the TAVI procedure. In brief,
the bypass graft or vessel of interest (native vessel was used
when possible) was engaged with a 6-F guiding catheter undernd CFR
ary ﬂow reserve (CFR) data. All patients had an improvem
rovement in CFR from baseline to follow-up was statistica
APV) pre- and post-hyperemia induction with adenosine
ssessment. The baseline APV values (pre-hyperemia) aﬂuoroscopic guidance. The coronary arterial circulation supplying
the left ventricle was assessed for either a native vessel or a saphenous
vein graft free of signiﬁcant angiographic stenosis (>30%) visualized
in the graft or in the target vessel beyond the distal graft anasto-
mosis. Following this a 0.014-inch Doppler-tipped coronary ﬂow
wire (FloWire, Volcano Corporation, San Diego, California) was
then inserted into the vessel of interest, with hemodynamic data
recorded using the Volcano s5 system. Intracoronary glyceryl tri-
nitrate 100 mg was then administered prior to the administration
of intracoronary adenosine. Adenosine was administered in 3 in-
crements using a concentration of 6 mg/ml to a dose of 120 mg to
induce maximal hyperemia. CFR was calculated as the ratio of
maximal hyperemic average peak velocity (APV) to pre-hyperemia
basal levels (APVpost/APVpre). The procedure was then repeated
immediately following TAVI, while the patient was still on the
procedure table, and again at a separate follow-up study 12 months
from the date of TAVI.
The target study size was 10 patients. Paired samples were
compared using paired Student t test or Wilcoxon matched pairs
rank-sum test (as appropriate based on whether the data was judged
as being parametrically distributed using the Shapiro-Wilk test).
Repeated-measures analysis of variance was used for multiple-
group comparisons. Calculations and analysis were performed us-
ing SAS JMP version 10.0.2.
Ten patients were enrolled in the study and underwent the initial
invasive assessment. However, 1 patient died during the follow-upent in CFR from baseline to 12-month assessment. (B) Serial mean CFR recordings
lly signiﬁcant using a repeated-measures analysis of variance analysis (p ¼ 0.0055).
immediately before transcatheter aortic valve implantation (TAVI), immediately post-
t each of the 3 time points were not statistically different from one another.
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1809period and another patient declined repeat invasive assessment due
to advanced age; therefore, data were available for 8 patients. All
patients had a mean atrioventricular gradient >40 mm Hg and
received CoreValve (Medtronic, Inc., Minneapolis, Minnesota)
implantation by the transfemoral approach. Mean aortic valve
pressure gradients as assessed by transthoracic echocardiography
decreased from 56.3 mm Hg (95% CI: 48.7 to 63.9 mm Hg) to
11.8 mm Hg (95% CI: 8.6 to 14.9 mm Hg; p < 0.01) at 12-month
follow-up.
Using a cutoff value for the CFR ratio of 2.5 (the expected
normal), all patients had impaired CFR prior to TAVI (mean CFR
1.53; 95% CI: 1.27 to 1.8). At follow-up invasive assessment at
a mean of 376 days, there was a signiﬁcant increase in CFR among
the 8 patients (mean absolute increase in CFR at follow-up vs. pre-
TAVI of 0.65; 95 CI: 0.36 to 0.93; p < 0.01) with a mean CFR
of 2.18 (95% CI: 1.88 to 2.47). Although there was a signiﬁcant
change from baseline pre-TAVI measurements to follow-up, there
was no signiﬁcant improvement in CFR immediately post TAVI
(mean change in CFR immediately post-TAVI vs. pre-TAVI of
0.045; 95% CI: 0.4 to 0.49; p ¼ 0.41). These data are also
demonstrated in Figures 1A and 1B, and Figure 1C demonstrates
the raw APV data pre- and post-hyperemia induction at each time
point. There were no adverse events as a result of the invasive CFR
evaluation. The vessel interrogated with the saphenous vein graft
to the left circumﬂex artery in 6 patients (native vessels too diseased
upstream) and the native left circumﬂex artery in 2 patients. Two
cardiologists trained in CFR assessment reviewed the raw traces
and made CFR measurements with the results compared for
interobserver variability. There were no statistically signiﬁcant
differences between the 2 sets of measurements, and both sets of
measurements independently (and when averaged) demonstrated
the same positive primary outcome.
Our data showed that treatment of AS by relieving the me-
chanical obstruction with TAVI led to a signiﬁcant improvement
in CFR at medium-term follow-up. This is the ﬁrst study to
demonstrate this serially using invasive assessments, although it has
been assessed indirectly using noninvasive techniques in 2 nonin-
vasive studies on patients undergoing conventional aortic valve
replacement (3,4).
Limitations of this study include the small sample size. However,
the difﬁculty of performing the current study (serial invasive
measurements sometimes requiring guide catheter cannulation
between CoreValve struts) may explain why it has not been done
previously. However, the magnitude of the change in the principal
variable is consistent with that in other previous noninvasive
studies.
In conclusion, we report that the treatment of severe AS with
TAVI led to a signiﬁcant improvement in coronary ﬂow dynamics
at 12-month follow-up as measured by CFR. This potentially
represents one of the key physiological pathways that is responsible
for symptomatic and prognostic improvement of patients with AS
who are treated with TAVI.Anthony C. Camuglia, MBBS (Hons)
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Versus End-Stage
Liver Disease
Two Different Entities
Kim et al. (1) have recently reported that the assessment of liver
function may be a useful tool in the prediction of prognosis in
patients with chronic heart failure (HF). Liver dysfunction is a
frequent ﬁnding in HF, especially if signs of accompanying right-
sided HF are present (2). Indeed, impairment of hepatic function
is typically caused by venous congestion as a result of backward
HF (2). Congestion of the liver and intestinal wall may promote
worse outcomes due to increased intestinal translocation and
decreased hepatic clearance of bacterial endotoxin resulting in
prognostically important activation of systemic inﬂammation (3,4).
Kim et al. (1) have used the MELD (Model of End Stage Liver
Disease) scoring system to assess the liver function in patients with
HF. The components of the MELD score, total bilirubin, serum
creatinine, and the international normalized ratio reﬂect, however,
not only liver dysfunction but also the prognostically relevant renal
failure and atrial ﬁbrillation (5–7); the last if patients are adequately
treated with oral anticoagulants. The use of the MELD score in
patients with chronic HF should, in our opinion, be understood as
assessment of all 3 comorbidities.
